CN107469087A - For antipsychotic preparation - Google Patents

For antipsychotic preparation Download PDF

Info

Publication number
CN107469087A
CN107469087A CN201710809408.7A CN201710809408A CN107469087A CN 107469087 A CN107469087 A CN 107469087A CN 201710809408 A CN201710809408 A CN 201710809408A CN 107469087 A CN107469087 A CN 107469087A
Authority
CN
China
Prior art keywords
milligrams
milligram
acid
preparation
antipsychotic
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201710809408.7A
Other languages
Chinese (zh)
Inventor
孙永丽
李丽
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Priority to CN201710809408.7A priority Critical patent/CN107469087A/en
Publication of CN107469087A publication Critical patent/CN107469087A/en
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/194—Carboxylic acids, e.g. valproic acid having two or more carboxyl groups, e.g. succinic, maleic or phthalic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A61K31/5513—1,4-Benzodiazepines, e.g. diazepam or clozapine

Abstract

The invention discloses one kind to be used for antipsychotic preparation, is made up of 12 milligrams of Clonazepam, 12 milligrams of Olanzapine, 12 milligrams of inner risperidone, 0.5 1 milligrams of cannabichromene, 0.5 1 milligrams of butanedioic acid, 0.5 1 milligrams of fumaric acid, 0.5 1 milligrams of benzoic acid, 0.5 1 milligrams of sorbic acid, 0.25 0.5 milligrams of glycine transporter inhibitors, 0.25 0.5 milligrams of alpha 7 nicotinic activator；The advantage of the invention is that：Be particularly suitable for use in it is manic it is uneasy, cry and laugh by turns, without any apparent reason, ruin thing hurt sb.'s feelings, be incoherent, few food of being insomnia, suspicious kind puzzled, the symptom such as the obstruction of the circulation of vital energy is fanatic mental patient, rapid-action, medicining cycle is short.

Description

For antipsychotic preparation
Technical field
It is specifically a kind of to be used for antipsychotic preparation the present invention relates to a kind of medicine, belong to drug field.
Background technology
The disease performance symptom of spiritual aspect, there is schizophrenia caused by brain dysfunction, various complicated societies, Psychological factor and the human body viscera functional disturbance caused by the pressure of various aspects that works, cause insomnia and dreamful sleep, suspicious anxiety, sorrow Strongly fragrant disease, labor degree of pondering over one's mistakes, the vain hope of absent-minded, illusion, excited restless, forced smile impermanence, paraphasia, unsociable and eccentric, mood is unusual, It is frightened etc..The disease of spiritual aspect, it is due to that a disorder occurs for brain function activity mostly, phrenoblabia occurs, either By human body viscera functional disturbance caused by various complicated social environment, psychological quality and operating pressures etc., and hereditary base Cause, it can result in the disease in terms of spirit.A kind of entitled " antipsychotic black/white preparation recipe " Application No. The Chinese invention patent of " 200610072884.7 " discloses a kind of antipsychotic black/white preparation recipe, and its black/white preparation is Two single components, it is made up of respectively antipsychotic drug and Clonazepam (clonazepam).Black preparation evening clothes, white preparation daytime Clothes.Each several bulk drugs of black/white preparation are subjected to single PROCESS FOR TREATMENT respectively.Black preparation can reach current various antipsychotics The effect of medicine, and have antianxiety, sedative-hypnotic property, the effect of white preparation can coordinate black preparation to reach antipsychotic drug, and have Antianxiety and antidepressant effect.However, the product works completely, medicining cycle length, cure rate is low, and has side effect.
The content of the invention
In order to solve the above problems, the present invention devises one kind and is used for antipsychotic preparation, is particularly suitable for use in manic It is uneasy, cry and laugh by turns, without any apparent reason, ruin thing hurt sb.'s feelings, be incoherent, few food of being insomnia, suspicious kind puzzled, the symptom such as the obstruction of the circulation of vital energy is fanatic mental patient, Rapid-action, medicining cycle is short.
The technical scheme is that：
It is composed of the following components for antipsychotic preparation：
Clonazepam 1-2 milligrams, Olanzapine 1-2 milligrams, inner risperidone 1-2 milligrams, cannabichromene 0.5-1 milligrams, amber Sour 0.5-1 milligrams, fumaric acid 0.5-1 milligrams, benzoic acid 0.5-1 milligrams, sorbic acid 0.5-1 milligrams, glycine transporter suppression Preparation 0.25-0.5 milligrams, alpha 7 nicotinic activator 0.25-0.5 milligrams.
Wherein, Clonazepam, Olanzapine, inner risperidone can be applied to manic uneasiness, cry as antipsychotics Laugh at it is variable, ruin thing hurt sb.'s feelings, be incoherent, few food of being insomnia, the suspicious kind puzzled, symptom such as the obstruction of the circulation of vital energy is fanatic；Cannabichromene, butanedioic acid, Fumaric acid, benzoic acid, sorbic acid, glycine transporter inhibitors, alpha 7 nicotinic activator can increase neurologic agent prescription Curative effect；
Preferably, 1.5 milligrams of Clonazepam, 1.5 milligrams of Olanzapine, 1.5 milligrams of inner risperidone, 1 milligram of cannabichromene, amber 0.5 milligram of amber acid, 0.5 milligram of fumaric acid, 0.5 milligram of benzoic acid, 0.5 milligram of sorbic acid, glycine transporter inhibitors 0.25 milligram, 0.25 milligram of alpha 7 nicotinic activator.
By using said components of the present invention, it is not only able to prevent and treat mental disease and phrenoblabia, second phase can also The adverse side effect of medicine is reduced or eliminated, meanwhile, curative effect of medication is improved, rapid-action, medicining cycle is short.
The advantage of the invention is that：Be particularly suitable for use in it is manic it is uneasy, cry and laugh by turns, without any apparent reason, ruin thing hurt sb.'s feelings, be incoherent, be insomnia it is few Food, the suspicious mental patient for being apt to the symptoms such as puzzled, the obstruction of the circulation of vital energy is fanatic, rapid-action, medicining cycle is short.
With reference to specific embodiment, the invention will be further described.
Embodiment
The preferred embodiments of the present invention are illustrated below, it will be appreciated that preferred embodiment described herein is only used In the description and interpretation present invention, it is not intended to limit the present invention.
Embodiment 1
It is composed of the following components for antipsychotic preparation：
1 milligram of Clonazepam, 1 milligram of Olanzapine, 1 milligram of inner risperidone, 0.5 milligram of cannabichromene, the milli of butanedioic acid 0.5 Gram, 0.5 milligram of fumaric acid, 0.5 milligram of benzoic acid, 0.5 milligram of sorbic acid, 0.25 milligram of glycine transporter inhibitors, α 7 0.25 milligram of nicotinic agonist.
Embodiment 2
It is composed of the following components for antipsychotic preparation：
2 milligrams of Clonazepam, 2 milligrams of Olanzapine, 2 milligrams of inner risperidone, 1 milligram of cannabichromene, 1 milligram of butanedioic acid, richness 1 milligram of horse acid, 1 milligram of benzoic acid, 1 milligram of sorbic acid, 0.5 milligram of glycine transporter inhibitors, alpha 7 nicotinic activator 0.5 Milligram.
Embodiment 3
It is composed of the following components for antipsychotic preparation：
1.5 milligrams of Clonazepam, 1.5 milligrams of Olanzapine, 1.5 milligrams of inner risperidone, 1 milligram of cannabichromene, butanedioic acid 0.5 Milligram, 0.5 milligram of fumaric acid, 0.5 milligram of benzoic acid, 0.5 milligram of sorbic acid, 0.25 milligram of glycine transporter inhibitors, α 7 0.25 milligram of nicotinic agonists.
By using said components of the present invention, it is not only able to prevent and treat mental disease and phrenoblabia, second phase can also The adverse side effect of medicine is reduced or eliminated, meanwhile, curative effect of medication is improved, rapid-action, medicining cycle is short.
100 are used through clinical patients, it is efficient up to 100%, and cure rate took effect up to 97%, 30 minutes after medication, worked It hurry up, medicining cycle is short.

Claims (2)

1. it is used for antipsychotic preparation, it is characterised in that composed of the following components：
Clonazepam 1-2 milligrams, Olanzapine 1-2 milligrams, inner risperidone 1-2 milligrams, cannabichromene 0.5-1 milligrams, amber Sour 0.5-1 milligrams, fumaric acid 0.5-1 milligrams, benzoic acid 0.5-1 milligrams, sorbic acid 0.5-1 milligrams, glycine transporter suppression Preparation 0.25-0.5 milligrams, alpha 7 nicotinic activator 0.25-0.5 milligrams.
2. according to claim 1 be used for antipsychotic preparation, it is characterised in that composed of the following components：
1.5 milligrams of Clonazepam, 1.5 milligrams of Olanzapine, 1.5 milligrams of inner risperidone, 1 milligram of cannabichromene, butanedioic acid 0.5 Milligram, 0.5 milligram of fumaric acid, 0.5 milligram of benzoic acid, 0.5 milligram of sorbic acid, 0.25 milligram of glycine transporter inhibitors, α 7 0.25 milligram of nicotinic agonists.
CN201710809408.7A 2017-09-10 2017-09-10 For antipsychotic preparation Pending CN107469087A (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN201710809408.7A CN107469087A (en) 2017-09-10 2017-09-10 For antipsychotic preparation

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CN201710809408.7A CN107469087A (en) 2017-09-10 2017-09-10 For antipsychotic preparation

Publications (1)

Publication Number Publication Date
CN107469087A true CN107469087A (en) 2017-12-15

Family

ID=60584746

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201710809408.7A Pending CN107469087A (en) 2017-09-10 2017-09-10 For antipsychotic preparation

Country Status (1)

Country Link
CN (1) CN107469087A (en)

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1791430A (en) * 2003-05-16 2006-06-21 辉瑞产品公司 Therapeutic combinations of atypical antipsychotics with GABA modulators, anticonvulsants or benzodiazapines
CN101939017A (en) * 2008-01-04 2011-01-05 Gw药品有限公司 Anti-psychotic composition comprising cannabinoids and anti-psychotic medicament
CN101977628A (en) * 2008-02-13 2011-02-16 塔加西普特公司 Alpha 7 nicotinic agonists and antipsychotics
CN102036654A (en) * 2008-07-24 2011-04-27 汉达医药有限责任公司 Stabilized atypical antipsychotic formulation
CN103068388A (en) * 2010-08-09 2013-04-24 霍夫曼-拉罗奇有限公司 Combination of glyt1 compound with antipsychotics

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1791430A (en) * 2003-05-16 2006-06-21 辉瑞产品公司 Therapeutic combinations of atypical antipsychotics with GABA modulators, anticonvulsants or benzodiazapines
CN101939017A (en) * 2008-01-04 2011-01-05 Gw药品有限公司 Anti-psychotic composition comprising cannabinoids and anti-psychotic medicament
CN101977628A (en) * 2008-02-13 2011-02-16 塔加西普特公司 Alpha 7 nicotinic agonists and antipsychotics
CN102036654A (en) * 2008-07-24 2011-04-27 汉达医药有限责任公司 Stabilized atypical antipsychotic formulation
CN103068388A (en) * 2010-08-09 2013-04-24 霍夫曼-拉罗奇有限公司 Combination of glyt1 compound with antipsychotics

Similar Documents

Publication Publication Date Title
Modabbernia et al. Intranasal oxytocin as an adjunct to risperidone in patients with schizophrenia: an 8-week, randomized, double-blind, placebo-controlled study
Boachie et al. Olanzapine use as an adjunctive treatment for hospitalized children with anorexia nervosa
Gonzalez et al. Neuroprotection in the newborn infant
Ricke et al. Induction of prolonged mania during ketamine therapy for reflex sympathetic dystrophy
Singla et al. Comparison of dexmedetomidine versus midazolam for intranasal premedication in children posted for elective surgery: a double-blind, randomised study
Rukma Glucagon for refractory anaphylaxis
CN107469087A (en) For antipsychotic preparation
Gross et al. Dread complications of catatonia: a case discussion and review of the literature
Syring Assessment and treatment of central nervous system abnormalities in the emergency patient
Ayatollahi et al. Two different concentrations of ketofol for procedural sedation and analgesia in closed reduction of nasal fracture
Araghi et al. Evaluation of the sedative effects of diazepam, midazolam, and xylazine after intranasal administration in juvenile ostriches (Struthio camelus)
Roberto et al. Adolescent catatonia successfully treated with Lorazepam and aripiprazole
Seeman Exercise and antipsychotic drugs
Teng et al. The use of bupropion in the treatment of restlessness after a traumatic brain injury
Stoové et al. Treading lightly: Finding the best way to use public health surveillance of hepatitis C diagnoses to increase access to cure
Manji et al. Severe undifferentiated vasoplegic shock refractory to vasoactive agents treated with methylene blue
Centers for Disease Control and Prevention (CDC Inadvertent use of Bicillin CR to treat syphilis infection--Los Angeles, California, 1999-2004
CA3180330A1 (en) Compositions and methods for treating neuropsychiatric disorders
CN105770357A (en) Use of alliin in preparation of antidepressants
Halbert Anti-N-methyl-D-aspartate receptor encephalitis: a case study
Zaidi et al. 59 “Lithium Damaged My Spine” Might not Be a Delusion After All
Montepío et al. Accidental placement of hemodialysis catheter tip in the right internal mammary vein: a case report
Reifler Play it again, Sam--depression is recurring
Hirata et al. Fatal hyperthermia following acute cervical spinal cord and head injury
Zhan et al. A Case of Severe Postop-erative Agitation and Literature Review

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
RJ01 Rejection of invention patent application after publication

Application publication date: 20171215

RJ01 Rejection of invention patent application after publication